TNFRSF8 and mature T-cell and NK-cell non-Hodgkin lymphoma: It demonstrated a better 5-year OS for BV + CHP compared to CHOP (75.1% vs. 61.0%, HR = 0.72) and led to the approval of BV + CHP as a front-line therapy for CD30-positive PTCL, which significantly influenced clinical practice.